[1]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
[2]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
[1]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
[2]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
[1]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
[1]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
[1]CurrentPatentAssignee:WILMINGTONPHARMATECHCOMPANYLLC;INCYTECORP-US2017/362229,2017,A1
Title: Matthew C. Stubbs, et al. Abstract 5071: Preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5071.